Eli Lilly stock price edges higher as FDA timeline for obesity pill comes into focus
Eli Lilly shares rose 0.3% to $1,036.46 Friday morning after an early dip, as investors tracked FDA review timing for its experimental obesity pill and new legal action from a compounding pharmacy. Early prescription data from Novo Nordisk’s rival Wegovy pill added pressure to the sector.